Import Alert Spurs Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP)
Westminster Pharmaceuticals, LLC is voluntarily recalling Levothyroxine and Liothyronine after FDA issues import alert affecting the active ingredient.
Editor's Note: The title of this article was revised on Aug. 16, 2018 to clarify that the recall applies to the combined product, Levothyroxine and Liothyronine (Thyroid Tablets, USP).
Westminster Pharmaceuticals, LLC announced on August 9, 2018 that it was voluntarily recalling all lots of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg to the wholesale level. The recall was initiated as a precaution after FDA placed the manufacturer of the API, Sichuan Friendly Pharmaceutical Co., Ltd., on import alert.
An FDA inspection of Sichuan Friendly Pharmaceutical Co., Ltd. performed in 2017 found deviations in current good manufacturing practices, which may pose a risk in product quality. The violations included failure to conduct residual solvent testing of API, failure to validate written procedures for equipment cleaning, failure to properly perform stability testing, and data control failures.
According to Westminster, Levothyroxine and Liothyronine (Thyroid Tablets, USP) for oral use is derived from porcine thyroid glands and contains both tetraiodothyronine sodium (T4 levothyroxine) and liothyronine sodium (T3 liothyronine). It is used to treat patients with hypothyroidism.
Westminster Pharmaceuticals, LLC stated in a press release that it had not received any reports of adverse events as of August 9. The recalled lots are packed in 100-count bottles. A complete list of recalled products can be found online.
Source: FDA
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
